US firm Advent to buy Sanofi's generics unit

April 17, 2018
Sanofi first announced its intention to sell Zentiva in 2015

US private equity firm Advent International has agreed to acquire Zentiva, French pharmaceutical giant Sanofi's European generics arm, for 1.9 billion euros ($2.4 billion), a statement said Tuesday.

"Advent's offer is firm, binding and fully financed," the statement from Advent and Sanofi said, adding that "the transaction is expected to close by the end of 2018".

The deal, which is still subject to regulatory approval, is one of a string of mega-mergers and acquisitions in the global pharmaceuticals sector in recent months.

Sanofi CEO Olivier Brandicourt first announced an intention to sell Zentiva in November 2015, shortly after taking the reins of the French company.

"Following a comprehensive review of strategic options for our generics unit in Europe, we have determined that transferring this business to Advent is the best option to ensure its long-term success," Brandicourt said in Tuesday's statement.

Advent said it aims to build Zentiva into a "new, independent, European generics leader".

According to Bloomberg News, should the sale go through, it would "add to the more than $15 billion in transactions that Sanofi has announced so far this year".

Sanofi took over Zentiva, which is based in Prague, in 2009.

According to its website, Zentiva traces its roots back to the 15th century Black Eagle pharmacy, one of the oldest in the Czech Republic.

Shares in Sanofi slid 0.3 percent while the Paris market was up 0.3 percent overall.

Explore further: Sanofi buys US haemophilia treatment firm for $11.6 bn (Update)

Related Stories

Sanofi buys US haemophilia treatment firm for $11.6 bn (Update)

January 22, 2018
French pharmaceutical firm Sanofi said Monday it had reached an agreement to purchase US biotech company Bioverativ, which specialises in treatments for haemophilia and rare blood disorders, for $11.6 billion.

Sanofi wins big in battle for nano-drug maker

January 29, 2018
France's Sanofi announced Monday that it had reached a deal to acquire Belgian biotech firm Ablynx that values the firm at 3.9 billion euros ($4.8 billion), beating out Danish rival Novo Nordisk for the nano-drug maker.

French pharma giant Sanofi says profits up in 2016

February 8, 2017
French pharmaceuticals giant Sanofi said Wednesday that cost-cutting measures and the strong performance of its rare diseases business drove up profits last year.

Sanofi profits hit by falling US sales of diabetes drugs

November 2, 2017
French pharmaceutical giant Sanofi on Thursday posted a drop in third-quarter earnings, hit by a decline in sales of its diabetes drugs in the United States.

Sanofi: No proof that vaccine linked to Philippines deaths

February 7, 2018
Drugmaker Sanofi insists there's no evidence of a link between the world's first dengue vaccine and children's deaths in the Philippines.

Sanofi aims for top spot in consumer health via asset swap

December 15, 2015
Sanofi said on Tuesday it hopes to take over the consumer health care unit of German peer Boehringer Ingelheim via an asset swap, making the French pharmaceutical giant the sector's world leader.

Recommended for you

Novel botulinum toxin compound relieves chronic pain

July 18, 2018
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to research by UCL, ...

FDA recalls heart medication valsartan, citing cancer concerns

July 17, 2018
The U.S. Food and Drug Administration issued a voluntary recall of several medications that contain the active ingredient valsartan, which is used to treat high blood pressure and heart failure.

Opioids given too easily to children: study

July 16, 2018
(HealthDay)—Many children are prescribed powerful opioid painkillers they don't really need, putting them and those around them at risk, a new study shows.

Study reveals opioid patients face multiple barriers to treatment

July 12, 2018
In areas of the country disproportionately affected by the opioid crisis, treatment programs are less likely to accept patients paying through insurance of any type or accept pregnant women, a new Vanderbilt study found.

Report details possible conflict of interest issues for FDA advisors

July 6, 2018
Charles Piller, a contributing correspondent for the journal Science, has published a Feature piece in the journal detailing what he describes as possible conflicts of interest issues by people who serve as advisors to the ...

Opioid epidemic responses overlook gender

July 5, 2018
Yale health experts warn that current efforts to confront the growth of opioid addiction and overdose deaths must better incorporate an understanding of how women fit into this epidemic.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.